Flow Cytometry Analysis of the Effect of IL-2 Addition on Reversing the Effect of IL-10 on SEB-Stimulated CD4+ T Cells: No IL-10 Pretreatment
| IL-2 (U/mL) . | IL-10 . | SEB . | Cell Cycle Distribution (%)6-150 . | ||
|---|---|---|---|---|---|
| G1 . | S . | G2/M . | |||
| 0 | − | − | >98 | <1 | <1 |
| 0 | − | + | 63.80 | 29.10 | 7.10 |
| 100 | + | + | 59.70 | 33.40 | 6.90 |
| 30 | + | + | 60.60 | 31.90 | 7.50 |
| 10 | + | + | 72.30 | 22.10 | 5.60 |
| 3 | + | + | 77.30 | 17.90 | 4.80 |
| 0 | + | + | 80.50 | 15.00 | 4.50 |
| 100 | − | + | 48.60 | 42.70 | 8.70 |
| 3 | − | + | 59.50 | 32.30 | 8.10 |
| 100 | + | − | 94.40 | 5.00 | 0.60 |
| 3 | + | − | 98.40 | 1.40 | 0.20 |
| 100 | − | − | 92.70 | 6.30 | 1.00 |
| 3 | − | − | 97.60 | 2.00 | 0.40 |
| IL-2 (U/mL) . | IL-10 . | SEB . | Cell Cycle Distribution (%)6-150 . | ||
|---|---|---|---|---|---|
| G1 . | S . | G2/M . | |||
| 0 | − | − | >98 | <1 | <1 |
| 0 | − | + | 63.80 | 29.10 | 7.10 |
| 100 | + | + | 59.70 | 33.40 | 6.90 |
| 30 | + | + | 60.60 | 31.90 | 7.50 |
| 10 | + | + | 72.30 | 22.10 | 5.60 |
| 3 | + | + | 77.30 | 17.90 | 4.80 |
| 0 | + | + | 80.50 | 15.00 | 4.50 |
| 100 | − | + | 48.60 | 42.70 | 8.70 |
| 3 | − | + | 59.50 | 32.30 | 8.10 |
| 100 | + | − | 94.40 | 5.00 | 0.60 |
| 3 | + | − | 98.40 | 1.40 | 0.20 |
| 100 | − | − | 92.70 | 6.30 | 1.00 |
| 3 | − | − | 97.60 | 2.00 | 0.40 |
PBMCs were treated simultaneously with IL-10 (10 U/mL), SEB (100 pg/mL), and IL-2 at the indicated concentrations for 5.5 days before flow cytometry analysis. Data were gated to analyze CD4+ T cells.